XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article

A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?

Read entire article

Aurora Innovation just got a $1M vote of confidence from its CEO — and major institutions like Uber, T. Rowe Price, and Morgan Stanley are all aboard. But with high cash burn, big ambitions, and a stock under $5, is this the moment to buckle up or bail out? 🚚💡🤖

Read entire article

Insiders and institutions are piling into Corsair Gaming (CRSR) just as revenue, margins, and product launches accelerate. With a new CFO, a strong Q3, and a massive PC upgrade cycle on deck, this stock could respawn in a big way — if management delivers.

Read entire article

Hershey Foods just got a major vote of confidence from its CEO and big institutions — but earnings are under pressure and cocoa costs are spiking. Is HSY a sweet buy on dips or an over-priced treat? Here’s the fun, funny, data-backed breakdown you won’t get anywhere else.

Read entire article

Sweetgreen (SG) just delivered a wild mix of insider buying, lowered guidance, widening losses, and surprising institutional support. With the CEO buying $1M+ of stock at the lows and valuation at historic discounts, the setup is intriguing — but still risky. Here’s the full FUNanc1al breakdown.

Read entire article

Insiders didn’t get the memo to stop buying AVTR — they doubled down. With a fresh CEO, a big new insider buy, and a $500M repurchase program, Avantor’s “boring but essential” lab empire might be setting up a comeback… if the experiment doesn’t explode first. 🧪📉➡️📈

Read entire article

Alarm.com is back on investors’ radar after a rare CEO insider buy and a tidal wave of institutional ownership. With growing SaaS revenue, real profitability, and a stock still far below its 2021 highs, ALRM may be setting up for a stealth rebound. Here’s the fun, funny, icon-filled breakdown of whether to rush in, hold steady, or panic responsibly.

Read entire article

Fox Factory (FOXF) went from high-flyer to face-plant, trading over 90% below its peak — yet the CEO and big institutions keep buying. Is this a stealth value opportunity or a suspension story that never quite rebounds? Let’s dig in, with jokes and numbers.

Read entire article

Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.

Read entire article